Purpose: Male lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) is common in men and can have negative effects on quality of life (QOL). It is the hope that this Guideline becomes a reference for effective evidence-based surgical management of LUTS/BPH.
BACKGROUND
BPH is a histologic diagnosis that refers to the proliferation of glandular epithelial tissue, smooth muscle, and connection tissue within the prostatic transition zone. 1 BPH is ubiquitous in the aging male with prevalence increasing with age. 2 BPH does not require treatment and is not the target of interventions; however, BPH can lead to an enlargement of the prostate (benign prostatic enlargement [BPE] ). The prostate may cause obstruction at the level of the bladder neck (benign prostatic obstruction). Obstruction may also be Parallel to these anatomical and functional processes, LUTS increase in frequency and severity with age. LUTS may be caused by a variety of conditions, including BPE and benign prostatic obstruction. In this Guideline, the Panel refers to "LUTS attributed to BPH" (LUTS/BPH) to indicate LUTS among men for whom an alternative cause is not apparent.
Since original publication 3 , a subset of the BPH Guideline panel worked on an amendment to the 2018 report given the interest in the newer technologies and to avoid the longer intervals in similar BPH Guideline efforts. 4 The Guideline panel provided the Minnesota Evidence Review Team with identical key questions, interventions, comparators, and outcomes as was the case in the 2018 effort. The review team worked with the panel to refine the scope, key questions, and inclusion/exclusion
The panel noted several topics, interventions and technologies had meaningful peer reviewed publications qualifying for additional statements, discussion and commentary. When the reviewed materials did not impact the 2018 AUA BPH Clinical Guidelines the statements were left unaltered without additional text.
Lower Urinary Tract Symptoms (LUTS)
In assessing the burden of disease, studies reveal a progressive increase in the prevalence of moderateto-severe LUTS, rising to nearly 50% by the eighth decade of life. 5 Others estimate that 90% of men between 45 and 80 years suffer some type of LUTS. 6 Although LUTS/BPH is not often life-threatening, the impact of LUTS/BPH on QoL can be significant and should not be underestimated.
Index Patient
The Index Patient is a male >45 who is consulting a clinician for his LUTS. He does not have a history suggesting non-BPH causes of LUTS, and his LUTS may or may not be associated with BPE, BOO, or BPH.
Sexual Dysfunction and Surgical Therapy
Given the strong observed relationship between erectile dysfunction (ED) and LUTS/BPH, this group of men is at high risk for sexual dysfunction. 7 Patients should be counselled about the sexual side effects of any surgical intervention and should be made aware that surgical treatment can cause ejaculatory dysfunction and may worsen ED.
Shared Decision Making
Patients should be provided with the risk/benefit profile for all treatment options in light of their circumstances to allow them to make informed decisions regarding their treatments.
GUIDELINE STATEMENTS
Evaluation and Preoperative Testing 1. Clinicians should take a medical history and utilize the AUA-Symptom Index and urinalysis in the initial evaluation of patients presenting with bothersome LUTS possibly attributed to BPH; select patients may also require post-void residual, uroflowmetry, or pressure flow studies. The Panel recognizes that "large" is a relative term as some providers have excellent results utilizing transurethral approaches (e.g., bipolar TURP, Holmium Laser Enucleation of the Prostate [HoLEP]) in prostates >60g. However, not all providers have access to or are using bipolar TURP or HoLEP technology, and may not wish to approach large glands transurethrally.
Alternatively, larger prostates have been treated with open simple prostatectomy. In recent years, alternative techniques have been developed that include laparoscopic and robot-assisted laparoscopic approaches.
Transurethral Incision of the Prostate (TUIP) 11 . TUIP should be offered as an option for patients with prostates £30g for the treatment of LUTS/BPH. ( 
U N C O R R E C T E D P R O O F
In a single center study comparing M-TURP, B-TURP and 120W PVP through 36 months supports the above insofar as there is similar change in International Prostate Symptom Score (IPSS) and IPSS-QOL between PVP and the TURP cohorts. 8, 9 Prostatic Urethral Lift (PUL) 14 . Clinicians should consider PUL as an option for patients with LUTS/BPH provided prostate volume <80g and verified absence of an obstructive middle lobe; however, patients should be informed that symptom reduction and flow rate improvement is less significant compared to TURP. (Moderate Recommendation; Evidence Level: Grade C).
There was a study of PUL that purposely treated men with obstruction including a middle lobe (a cystoscopic exclusion from previous randomized control trial [RCT] ). We reviewed and excluded this study by Rukstalis et al. because it is not a randomized trial. 10 The study is a "nonrandomized cohort" that used criteria identical to the LIFT trial except for some defined variables. It is essentially a case series with pre-post outcomes. For this reason the statement above in which PUL must "verify absence of an obstructive middle lobe" remains unchanged in this update. 15 . PUL may be offered to eligible patients concerned with erectile and ejaculatory function for the treatment of with LUTS/BPH. (Conditional Recommendation; Evidence Level: Grade C).
Transurethral Microwave Therapy (TUMT) 16 . TUMT may be offered to patients with LUTS/BPH; however, patients should be informed that surgical retreatment rates are higher compared to TURP. (Conditional Recommendation; Evidence Level: Grade C).
Water Vapor Thermal Therapy 17 . Water vapor thermal therapy may be offered to patients with LUTS/BPH provided prostate volume <80g; however, patients should be informed that evidence of efficacy, including longer-term retreatment rates, remains limited. (Conditional Recommendation; Evidence Level: Grade C).
Three-year results showed sustained improvements for the IPSS IPSS-QoL, and Qmax, with scores remaining significantly improved from baseline; Qmax improvement was > 50% from 3 to 24 months and 39% at 36 months. 11 At 36 months in the intent-to-treat population of the original 136 participants, mean change from baseline in IPSS was -11.0 points and the mean score was 10.4 points, representing a 50% improvement from baseline. Mean IPSS-QoL was improved from baseline by 49% at 3 years. Because this additional paper demonstrating durable outcomes out to three years was not a second cohort the Conditional Recommendation and Evidence Level: Grade C from the 2018 AUA Guideline remain unchanged. 18 . Water vapor thermal therapy may be offered to eligible patients who desire preservation of erectile and ejaculatory function. (Conditional Recommendation; Evidence Level: Grade C).
In the RCT comparing water vapor thermal therapy to sham, the original 136 patients randomized to water vapor thermal therapy are expected to be followed for five years. 12 At 36 months, no de novo ED was reported but dysuria was reported by 1% of participants. 12e14 No significant changes in IIEF-EF scores were observed compared to baseline.Bother and function scores associated with ejaculation, assessed by the MSHQ-EjD, were significantly improved at 12 and 36 months following treatment, P[.006 and P[.003 respectively.
Transurethral Needle Ablation (TUNA) 19 . TUNA is not recommended for the treatment of LUTS/BPH. (Expert Opinion).
The lack of peer-reviewed publication in the literature review timeframe meeting the inclusion criteria and the decreasing clinical relevance resulted in a lack of enthusiasm by the Panel to recommend TUNA for the treatment of LUTS attributed to BPH. Aquablation surgery utilizes a robotic handpiece, console and conformal planning unit (CPU). The technique is not in the MIST category as patients must undergo general anesthesia. The resection of the prostate is performed using a water jet from a transurethrally placed robotic handpiece. After completion of the resection, electro-cautery via a standard cystoscope/resectoscope or traction from a 3 way catheter balloon are used to obtain hemostasis.
One low risk of bias RCT (n [ 181) assessing Aquablation was evaluable by the panel. 15e17 The trial utilized standard inclusion/exclusion criteria limiting participants to prostate sizes between 30-80 grams. Treatment response through 12 months, defined as at least a 5-point improvement in International Prostate Symptom Score (IPSS), was similar for Aquablation and TURP (Quality of Evidence: Moderate). Mean improvement in lower urinary tract At 3 months, Aquablation resulted in fewer harms classified as Clavien-Dindo grade 2 compared to TURP, 26% versus 42%, P[.015. 15, 16 Additionally, rates of retrograde ejaculation were higher (P[.002) with TURP (23%) compared to Aquablation (6%). Other harms occurring at similar rates in both groups, and classified as Clavien-Dindo grades 1-4, included bladder spasms, bleeding, dysuria, pain, and urethral damage. No deaths were reported. Also at 3 months, reduction in prostate volume was significantly less with Aquablation (31%) compared to TURP (44%) (P[.007). 15, 16 Among a non-random subset of sexually active men, the proportion of subjects who reported worsening sexual function through 6 months on the IIEF-5 (6-point decrease) or the Male Sexual Health Questionnaire (MSHQ-EjD) (2-point decrease) was 33% in the Aquablation group compared with 56% in TURP group (P[.03). 15, 16 Prostate Artery Embolization (PAE) 22. PAE is not recommended for the treatment of LUTS/ BPH outside the context of a clinical trial. (Expert Opinion).
PAE is a newer, largely unproven MIST for BPH. High level evidence remains sparse, and the overall quality of the studies is uniformly low. Some of the deficiencies of the included trials include 1. A lack of randomization, 2. High levels of susceptibility to selection, detection, attrition, and reporting biases, 3. The common inclusion of a preoperative status of urinary retention, and 4. The absence of standard inclusion/exclusion criteria for a LUTS/BPH RCT.
Three RCTs (n[247) were identified comparing PAE to TURP; however, there was substantial heterogeneity between the two trials (I 2 [ 90%). 18e20 One trial reported outcomes up to 2 years, one up to 12 months, and the other only through 12 weeks. There was substantial heterogeneity between trials and pooled results must therefore be interpreted with caution. Definitions of and outcomes for subjective symptom response varied substantially between trials. One trial reported the proportion of responders, defined as achieving an IPSS score 8 points and/or a QoL 3 points, was similar between the PAE and TURP groups (RR 0.9 [95%CI 0.7 to 1.1]; low quality of evidence). 18 Success through 12 months was reported for 87% of the PAE participants compared with 100% in the TURP group. Overall, results at intermediate term follow-up (>3 to 12 months) were similar between groups (WMD 4.8 points [95% CI -2.9 to 12.5]; very low quality of evidence). 18, 19 The smallest trial (n[30) reported substantially greater improvement in symptoms with TURP compared with PAE (MD 9 points [95% CI 4.6 to 13.1]) 18 and the other (n[107) reported no significant difference between the groups at 3 and 12 months. 19 The need for reoperation was reported for 7 participants in the PAE group compared with 2 in the TURP group (RR 2.9; CI: 0.7, 11.9; very low quality of evidence). Two trials found incidences of sexual dysfunction to be higher with TURP compared with PAE. 18, 20 One trial reported all 15 TURP participants experienced retrograde ejaculation while no cases were reported among PAE participants. 18 The short-term trial found incidence of ejaculatory dysfunction was lower with PAE (56%) compared with TURP (84%) after 12 weeks (RR 0.67 [95%CI 0.45 to 0.98). 20 One trial reported a higher incidence of acute urinary retention requiring re-catheterization in the PAE group (26%) versus the TURP group 6%, P[.004).
Given the heterogeneity in the literaturedand concerns regarding radiation exposure, post-embolization syndrome, vascular access, technical feasibility, and quality control at lower volume centersdit is the opinion of the Panel that PAE should only be performed in the context of a clinical trial until sufficient evidence from rigorously performed studies is available to indicate definitive clinical benefit. The Panel recommends trials involve multi-disciplinary teams of urologists and radiologists; and that, as with other MIST therapies, RCTs comparing PAE to sham be considered to account for significant placebo effects. In support of the concept of 120W PVP use in anticoagulated patients, recent publications report that the need for a blood transfusion was lower for photoselective vaporization prostatectomy 120W compared to TURP. 8, 9 
FUTURE DIRECTIONS
There are enormous gaps in knowledge and, therefore, ensuing opportunities for discovery. These include but are not limited to many unanswered While these guidelines do not necessarily establish the standard of care, AUA seeks to recommend and to encourage compliance by practitioners with current best practices related to the condition being treated. As medical knowledge expands and technology advances, the guidelines will change. Today these evidence-based guidelines statements represent not absolute mandates but provisional proposals for treatment under the specific conditions described in each document. For all these reasons, the guidelines do not pre-empt physician judgment in individual cases.
Treating physicians must take into account variations in resources, and patient tolerances, needs, and preferences. Conformance with any clinical guideline does not guarantee a successful outcome.
The guideline text may include information or recommendations about certain drug uses ('off label') that are not approved by the Food and Drug Administration (FDA), or about medications or substances not subject to the FDA approval process. AUA urges strict compliance with all government regulations and protocols for prescription and use of these substances. The physician is encouraged to carefully follow all available prescribing information about indications, contraindications, precautions and warnings. These guidelines and best practice statements are not in-tended to provide legal advice about use and misuse of these substances.
Although guidelines are intended to encourage best practices and potentially encompass available technologies with sufficient data as of close of the literature review, they are necessarily time-limited. Guidelines cannot include evaluation of all data on emerging technologies or management, including those that are FDA-approved, which may immediately come to represent accepted clinical practices.
For this reason, the AUA does not regard technologies or management which are too new to be addressed by this guideline as necessarily experimental or investigational.
